Supplementary appendix

Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Borchmann P, Haverkamp H, Lohri A, et al. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin s lymphoma treated with BEACOPP escalated alone or in combination with rituximab (HD8): an open-label, international, randomised phase study by the German Hodgkin Study Group. Lancet Oncol 07; published online Feb. http://dx.doi.org/0.06/s470-045(7)00-.

HD8: Outcome of interim PET- positive advanced stage Hodgkin lymphoma Web extra material Appendix : Inclusion and exclusion criteria, procedures and endpoints Complete Inclusion and exclusion criteria Entry criterion for the trial was a newly diagnosed, histology-proven Hodgkin Lymphoma (HL) in Ann-Arbor stage IIB with large mediastinal mass ( one third of the maximal thoracic diameter) or extranodal lesions; or in stage III and IV. Patients had to be between 8 and 60 years of age, previously untreated for HL, with personally signed written informed consent, consent to storage of study data and required tissue samples, organ function (except HL-related impairments), a negative human immunodeficiency virus (HIV)-test, a negative pregnancy test in women, and a life expectancy of more than months. Exclusion criteria included incomplete staging diagnosis, and prior or concurrent disease disallowing protocol treatment, in particular chronic obstructive pulmonary disease with global insufficiency, symptomatic coronary heart disease, cardiomyopathy or cardiac insufficiency (New York Heart Association value of ejection fraction < 50% or fractional shortening < 5%), serious uncontrolled hypertension, uncontrollable infection, leukocyte concentration <,000/mm³ or thrombocyte concentration < 00,000/ mm³ (exception: reduced values related to Hodgkin's disease, e.g. bone marrow infiltration, splenomegaly), creatinine clearance < 60 ml/min, bilirubin > mg/dl or glutamic oxaloacetic transaminase > 00 U/l or glutamic pyruvic transaminase > 00 U/I (exception: elevated values due to HL liver involvement), poorly controlled diabetes mellitus (HbAc > 7.5 %), elevated fasting blood sugar > 00 mg/dl, HIV-Infection, chronic active hepatitis B and/or hepatitis C, or stabilityendangering bone involvement that precludes from an FDG-PET examination. Patients were also excluded from the study if they were pregnant or lactating, had HL as part of a composite lymphoma, a previous malignant disease within the last 5 years, prior chemo- or radiotherapy, an Eastern Cooperative Oncology Group performance status >, long-term ingestion of corticosteroids or antineoplastic drugs or a known intolerance to any of the study drugs, received antiepileptic treatment, lacked accountability, had conditions indicative of noncompliance to trial procedures, used unsafe contraceptive methods (Pearl index > ), had a relationship of dependence or employer-employee relationship to the sponsor or the investigator, were committed to an institution on judicial or official order, or participated in another interventional trial that could interact with this trial. Required entry criteria for an FDG-PET assessment after cycles of treatment and thus randomization were chemotherapy administered according to the HD8 protocol and tumor response to chemotherapy. Staging examinations Staging and pre-treatment evaluation contained medical history, physical examination, chest radiography, computed tomography (CT) scan of the neck, chest, abdomen and pelvis, ultrasound of the abdomen, biopsy of an involved lymph node or of another primarily involved organ, bone marrow biopsy, skeletal scintigraphy, serum chemistry, lung function test, thyroid function test, electro- and echocardiography, and gonadal function. Biopsy material was centrally reviewed by at least one member of a panel of six HL pathology experts. Response Assessment Response to treatment was evaluated after cycles of chemotherapy, in the week after the last dose of chemotherapy and after completion of radiotherapy, if applicable. Response had to be documented for each initially involved region using adequate methods (CT-scan, ultrasound, bone scintigraphy, bone marrow biopsy, and bone marrow cytology). In doubtful cases, histological clarification was recommended for the final staging conducted. Additionally, 8 F-FDG-PET was a mandatory examination after cycles of chemotherapy for all patients with responding disease after treatment per protocol and at least 4 weeks after the last chemotherapy infusion for patients in partial remission, with residual tissue of at least 5 cm in the greatest cross-sectional diameter after treatment according to protocol. In the follow-up period, physical examination, laboratory tests, chest X-ray, pulmonary function, abdominal ultrasound, thyroid diagnostics, echocardiography, ECG, assessment of gonadal function and self-assessment of quality-of-life were requested at defined intervals. Provided complete response had been reached, CT-scans were to be used only in cases of suspected tumour recurrence. Response Criteria Responses were defined as follows: Complete Remission, CR: disappearance of all clinical and radiological symptoms. CR with residual tissue, CRu: residual radiological abnormalities compatible with CR in the definitive restaging, if there were no other signs of lymphoma activity. Outcome was also judged as CRu in all cases where a patient with non-cr according to the final restaging did not receive any further treatment for the six months following end of primary treatment. Partial Remission, PR: continuing presence of lymphoma tissue (clinical, radiological) with significant reduction in all involved sites, shrinkage of the majority (at least half) of

HD8: Outcome of interim PET- positive advanced stage Hodgkin lymphoma large involved lymph nodes and localized measurable organ manifestations (with more than cm in diameter) by more than 50% compared with the initial status. If no lesion had more than cm in diameter: shrinkage of the two largest involved lesions by more than 50% in greatest diameter; shrinkage of a large mediastinal mass (if present) by more than 50% in the maximum transverse diameter; and absence of B-symptoms and of rising or strongly elevated ESR. No Change, NC: active lymph node tissue present and criteria for PR not reached (i.e. either overall too little shrinkage in all sites or inadequate shrinkage in particular sites or strongly elevated ESR and/or B-symptoms) and no other node enlarged by more than 5% in largest diameter. Progressive disease, PD: occurrence of new lesions or increase of at least one already known lesion by more than 5% during or within months after therapy or after non-cr as final treatment outcome. Study Endpoints The primary efficacy endpoint of this study was progression-free survival (PFS) defined as follows: Starting date for PFS was the date of completion of all staging examinations as recorded on the staging case report form. Its duration was defined as survival until progression, relapse, or death from any cause and was censored at the date of last information on the disease status. The secondary endpoint Overall Survival (OS) was calculated from the same starting date as PFS. It was defined as time to death of any cause and censored at the date of last information. Median follow-up was calculated by the reverse Kaplan-Meier method. Chemotherapy BEACOPP escalated was administered with dose levels given in table. Individual cycles were repeated on day. BEACOPP escalated was generally administered in an out-patient setting except for the first cycle, for which hospital admission was recommended. Bleomycin and vincristine were to be administered even if leukopenia was observed on day 8. In case of non-haematological events (fever, infection or signs thereof, etc.), day 8 was to be eliminated without substitution. Start of the next cycle was postponed until recovery if the white blood count (WBC) was less than,500/µl or the platelet count less than 80,000/µl on the day scheduled for retreatment or in case of serious unexpected non-haematological side-effects with CTCAE toxicity grade or 4. A dose reduction strategy was put into effect if any of the following toxic events occurred: leukopenia CTC Grade 4 for more than 4 days (WBC <,000/mm³), thrombopenia CTC Grade 4 on one or more days (platelet count < 5,000/mm³), infection CTC Grade 4; or other toxicity CTC Grade 4, e.g. mucositis. BEACOPP escalated was reduced by one dose level for all subsequent cycles if any of these events or a treatment postponement of more than weeks due to inadequate recovery of blood values occurred. If any toxic event occurred in successive cycles, the remaining cycles were to be administered at baseline dose. Further possible reductions followed the dose reduction scheme from baseline dose. Treatment postponements of less than 5 days were no reason to reduce dose if caused by inadequate blood value recovery only. In case of drug-specific intolerance (e.g. vincristine neuropathy, procarbacine allergy), single drugs could be dropped from the regimen without substitution. Substance application Day of cycle Dose level (starting at escalated level) escalated level level level baseline Cyclophosphamide i.v.,50,00 950 800 650 Adriamycin i.v. 5 5 5 5 5 Etoposide or Etopside phosphate* i.v. - 00 75 50 5 00 Procarbazine p.o. -7 00 Prednisone p.o. -4 40 Vincristine i.v. 8 4 (max. mg total) Bleomycin i.v. 8 0 G-CSF (daily or pegylated) s.c. (from) day 4 Data are mg/m², unless indicated otherwise. *Etoposide phosphate as etoposide-equivalent dose: mg etoposide phosphate is equivalent to 00mg etoposide. This difference is due to different molecular weights. Table : BEACOPP dose levels.

HD8: Outcome of interim PET- positive advanced stage Hodgkin lymphoma Appendix : Participating study centres Number of recruited patients Principal investigator, recruiting centre (Germany unless indicated) 0 Prof. Dr. med. Andreas Engert, Klinik I für Innere Medizin / Studienzentrum, Universitätsklinik Köln, Köln Dr. med. Jana Markova, Oddelení klinické hematologia, Fakultni Nemocnice, Prag 0, Czech Republic Prof. Dr. med. Helmut Ostermann, Med. Klinik III für Hämatologie / Onkologie, Klinikum Großhadern, München Mag. Matthias Florian, Arbeitsgemeinschaft Medikamentöse Tumortherapie ggmbh (coordination for all Austrian 0 centres) 9 Dr. med. Hans-Joachim Beck, Abteilung für Hämatologie, Gebäude 605, Universitätsklinik Mainz, Mainz 8 Dr. med. Julia Meissner, Medizinische Klinik und Poliklinik V, Universitätsklinikum Heidelberg, Heidelberg 8 Prof. Dr. Ulrich Bernd Keller, Medizinische Klinik III, Klinikum "Rechts der Isar", München 8 Prof. Dr. med. Judith Dierlamm, Abt. Hämatologie / Onkologie, Universitätsklinikum Hamburg-Eppendorf, Hamburg 7 Dr. med. Stephan Mathas, Medizinische Klinik, Hämatologie / Onkologie, Campus Virchow Klinikum, Berlin Prof. Dr. med. Bernd Hertenstein, Med. Klinik I, Abt. Hämatologie/ Onkologie, Klinikum Bremen Mitte ggmbh, 7 Bremen 7 Priv. Doz. Dr. med. Michaela Feuring-Buske, Innere Abteilung III, Universitätsklinikum Ulm, Ulm Prof. Dr. med. Georg Maschmeyer, Medizinische Klinik, Hämatologie/ Onkologie, Klinikum Ernst von Bergmann, 7 Potsdam 6 Prof. Dr. med. Dietger Niederwieser, Medizinische Klinik II, Hämatologie, Universitätsklinik Leipzig, Leipzig 6 Dr. med. Felicitas Hitz, Onkologie, Kantonsspital St. Gallen, St. Gallen, Switzerland 6 Prof. Dr. med. Ulrich Dührsen, Klinik für Hämatologie / WTZ Ambulanz, Universitätsklinik Essen, Essen 6 Dr. med. Erhardt Schäfer, Gemeinschaftspraxis, Bielefeld 6 Prof. Dr. med. Mathias Rummel, Med. Klinik IV, Hämatologie / Onkologie, Justus-Liebig-Universität Gießen, Gießen Dr. med. Wolfram Jung, Abteilung Hämatologie und Onkologie, Universitätsklinikum der Georg-August-Universität, 5 Göttingen 5 Dr. med. Julia Thiemer, Innere Medizin Hämatologie / Onkologie, Klinikum der Philipps-Universität, Marburg 5 Prof. Dr. med. Christian Meyer zum Büschenfelde, Medizinische Klinik II, Asklepios Klinik Altona, Hamburg 5 Prof. Dr. med. Martin Grießhammer, Abteilung Hämatologie / Onkologie, Klinikum Minden, Minden 5 Dr. med. Walter Lindemann, Klinik für Hämatologie und Onkologie, Katholisches Krankenhaus Hagen GmbH, Hagen 5 Dr. med. Tobias Gaska, Klinik für Hämatologie / Onkologie, Brüderkrankenhaus St. Josef Paderborn, Paderborn 5 Priv. Doz. Dr. med. Jürgen Richard Fischer, Med. Klinik II, Klinik Löwenstein ggmbh, Löwenstein 5 Dr. med. Martin Sökler, GCP-Studienzentrale der Inneren Medizin II, Eberhard-Karls-Universität, Tübingen 4 Prof. Dr. med. Max Topp, Med. Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg 4 Dr. med. Ulrich von Grünhagen, Praxis Innere Medizin, Cottbus 4 Priv. Doz. Dr. med. Ullrich Graeven, Medizinische Klinik I, Kliniken Maria Hilf GmbH, Mönchengladbach 4 Prof. Dr. med. Michael Pfreundschuh, Innere Medizin I, Universitätsklinikum des Saarlandes, Homburg 4 Prof. Dr. med. Stefan Krause, Medizinische Klinik V, Universitätsklinik Erlangen, Erlangen 4 Prof. Dr. med. Dietrich Peest, Abteilung Hämatologie / Onkologie, Med. Hochschule Hannover, Hannover 4 Prof. Dr. med. Walter Aulitzky, Innere Medizin II, Hämatologie / Onkologie, Robert-Bosch-Krankenhaus, Stuttgart 4 Dr. med. Martin Vogelhuber, Klinik und Poliklinik für Innere Medizin III, Universitätsklinik Regensburg, Regensburg Dr. med. Daniel Schöndube, Klinik für Hämatologie, Onkologie und Palliativmedizin, HELIOS Klinikum Bad Saarow, 4 Bad Saarow 4 Priv. Doz. Dr. med. Thomas Pabst, Klinik und Poliklinik für Med. Onkologie, Inselspital Bern, Bern, Switzerland 4 Dr. med. Fatime Krasniqi, Onkologie, Universitätsspital Basel, Basel, Switzerland 4 Prof. Dr. med. Jan Hastka, III. Medizinische Klinik, Universitätsklinikum Mannheim GmbH, Mannheim Prof. Dr. med. Helga Bernhard, Med. Klinik V / Hämatologie, Klinikum Darmstadt GmbH, Darmstadt Prof. Dr. med. Jörg Mezger, Medizinische Klinik, Abt. II Hämatologie / Onkologie, St. Vincentius-Kliniken gag, Karlsruhe Dr. med. Tom Vieler, Karl Lennert-Krebscentrum, II. Medizinische Klinik, Universitätsklinik Schleswig-Holstein, Kiel Priv. Doz. Dr. med. Emanuele Zucca, Oncology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland Dr. med. Andreas Rank, Medizinische Klinik II, Klinikum Augsburg, Augsburg

HD8: Outcome of interim PET- positive advanced stage Hodgkin lymphoma Dr. med. Oliver Schmalz, Med. Klinik I, Hämatologie/ Onkologie, Helios Klinikum Wuppertal, Wuppertal Prof. Dr. med. Wolf-Dieter Ludwig, Hämatologie, Onkologie und Tumorimmunologie, HELIOS Klinikum Berlin-Buch, Berlin Prof. Dr. med. Yon Ko, Innere Medizin I, Johanniter-Krankenhaus, Bonn Prof. Dr. med. Dirk Behringer, Klinik für Hämatologie, Onkologie und Palliativmedizin, Augusta-Kranken-Anstalt ggmbh, Bochum Dr. med. Christian Marin, Abteilung Hämatologie / Onkologie, Helios Kliniken Schwerin, Schwerin Prof. Dr. med. Markus Bangerter, Gemeinschaftspraxis Innere Medizin, Augsburg Priv. Doz. Dr. med. Bernd Metzner, Innere Medizin II, Klinikum Oldenburg, Oldenburg Dr. med. Dagmar Kühnhardt, Zentrum für Innere Medizin, Hämatologie / Onkologie, Charité Campus Mitte, Berlin Dr. med. Zijlstra, Dept. of Hematology, VU University Medical Center, Amsterdam, The Netherlands Prof. Dr. med. Frank Griesinger, Hämatologie und Internistische Onkologie, Pius-Hospital, Oldenburg Prof. Dr. med. Alexander Kiani, Medizinische Klinik IV, Klinikum Bayreuth, Bayreuth Dr. med. Joachim Zimber, Internistische Gemeinschaftspraxis, Nürnberg Dr. med. Norbert Fischer, Hämatologie, Onkologie, Immunologie, Klinikum Schwabing, München Prof. Dr. med. Martin Wilhelm, Klinik V Onkologie / Hämatologie, Klinikum Nürnberg, Nürnberg Prof. Dr. med. Tim H. Brümmendorf, Medizinische Klinik IV, Med. Fakultät der RWTH Aachen, Aachen Prof. Dr. med. Elke Jäger, II. Medizinische Klinik, Krankenhaus Nordwest, Frankfurt Prof. Dr. med. Ulrich Kaiser, Medizinische Klinik II, St. Bernward-Krankenhaus, Hildesheim Dr. med. Georg Köchling, Netzwerk Onkologie, Schwarzwald-Baar-Heuberg - Standort Villingen, Villingen- Schwenningen Dr. med. Georg Schliesser, Gemeinschaftspraxis Hämatologie-Onkologie Gießen,, Gießen Dr. med. Felix Marquard, Onkologische Schwerpunktpraxis Celle, Celle Dr. med. Karl Verpoort, Überörtliche Gemeinschaftspraxis, Hamburg Mohammed Wattad, Zentrum für Innere Medizin, Evangelisches Krankenhaus, Essen Prof. Dr. med. Norbert Schmitz, Hämatologische Abteilung, Asklepios Klinik St. Georg, Hamburg Dr. med. Bernhard Göttler, Onkologische Gemeinschaftspraxis,, Muhr am See Dr. med. Enrico Schalk, Klinik für Hämatologie / Onkologie, Universitätsklinikum Magdeburg A. ö. R., Magdeburg Dr. med. Dirk Tummes, Gemeinschaftspraxis, Aachen Prof. Dr. med. Wolff Schmiegel, Medizinische Klinik, Knappschaftskrankenhaus, Bochum Dr. med. Mathias Schmid, Institut für med. Onkologie und Hämatologie, Stadtspital Triemli, Zürich, Switzerland Dr. med. Volker Burstedde, Überregionale Gemeinschaftspraxis, Bocholt Dr. med. Sebastian Müller, Gemeinschaftspraxis Innere Medizin, Ansbach Dr. med. Michael Schaefers, Gemeinschaftspraxis Innere Medizin, Duisburg Priv. Doz. Dr. med. Gerald Meckenstock, Abteilung für Onkologie und Hämatologie, St. Josef-Hospital Gelsenkirchen- Horst, Gelsenkirchen Prof. Dr. med. Stephan Schmitz, Onkologische Schwerpunktpraxis, Köln Dr. med. Mike Haberkorn, Praxis Innere Medizin, Landshut Dr. med. Norbert Grobe, Innere Med./Hämatol. Abt., Dietrich-Bonhoeffer-Klinikum, Neubrandenburg Sven Dyrda, Klinik für Internistische Onkologie / Hämatologie, Kliniken Essen-Mitte, Essen Dr. med. Markus Sieber, Medizinische Klinik, Kreiskrankenhaus Gummersbach, Gummersbach Dr. med. Axel Florschütz, Abt. Hämatologie/ Onkologie, Städtisches Klinikum Dessau, Dessau Prof. Dr. med. H.G. Derigs, KIM, Klinikum Frankfurt Höchst GmbH, Frankfurt Dr. med. Dietmar Reichert, Hämatologie und Internistischen Onkologie, Ubbo-Emmius Klinik, Aurich Prof. Dr. med. Norbert Frickhofen, Innere Medizin III, Hämatologie / Onkologie, Wiesbaden Dr. med. Veronika Ballova, Onkologie KSB, Kantonsspital Baden, Baden, Switzerland Prof. Dr. med. Winfried Gassmann, Med. Klinik III Hämatologie / Onkologie, St. Marien-Krankenhaus, Siegen Dr. med. Panagiotis Samaras, Onkologie, Universitätsspital Zürich, Zürich, Switzerland Dr. med. Miriam Ahlborn, Medizinische Klinik III, Städtisches Klinikum Braunschweig, Braunschweig Dr. med. Karin Heinisch, Medizinische Klinik II, Klinikum Lippe-Lemgo, Lemgo 4

HD8: Outcome of interim PET- positive advanced stage Hodgkin lymphoma Prof. Dr. med. Wolfram Brugger, Klinik II für Innere Medizin, Schwarzwald-Baar Klinikum VS GmbH, Villingen- Schwenningen Dr. med. Matthias Respondek, Praxis für Innere Medizin, Stuttgart Prof. Dr. med. Michael Geißler, Innere Medizin, Kliniken Esslingen, Esslingen Dr. med. Andrea Kerkhoff, Innere Medizin A, Universitätsklinik Münster, Münster Priv. Doz. Dr. med. Hartmut Kirchner, Hämatologie und Onkologie, KRH Klinikum Siloah-Oststadt-Heidehaus (SOH), Hannover Dr. med. Christina Große-Thie, Medizinische Klinik III, Hämatologie, Onkologie, Palliativmedizin, Universitätsklinikum Rostock AöR, Rostock Prof. Dr. med. Volker Runde, Hämatologie/Onkologie, Wilhelm-Anton-Hospital ggmbh Goch, Goch Dr. med. Harald Held, Hämatologie, Onkologie u. Nephrologie, FEK Friedrich-Ebert-Khs.Neumünster GmbH, Neumünster Dr. med. Matthias Zaiss, Onkologische Schwerpunktpraxis, Freiburg Prof. Dr. med. Hartmut Link, Innere Medizin I / Hämatologie, Westpfalz Klinikum GmbH, Kaiserslautern Dr. med. Bärbel Schädlich, Gemeinschaftspraxis für Innere Medizin,, Halle Dr. med. Georg Jacobs, Praxis für Hämatologie und Onkologie, Saarbrücken Priv. Doz. Dr. med. Ulrich Mey, Medizinische Onkologie, Kantonsspital Graubünden, Chur, Switzerland Dr. med. Paraskevi Tatsis, Praxis, Buchholz Dr. med. Michael Eckart, Gemeinschaftspraxis, Erlangen Prof. Dr. med. Rudolf Weide, InVO-Institut für Versorgungsforschung in der, Onkologie GbR, Koblenz Dr. med. Judith Neukirchen, Abteilung für Hämatologie, Onkologie, Universitätsklinikum Düsseldorf, Düsseldorf Dr. med. Christoph Plöger, Mannheimer Onkologiepraxis, Mannheim Priv. Doz. Dr. med. Peter Staib, Abt. für Hämatologie / Onkologie, St. Antonius Hospital, Eschweiler Dr. med. Ali Aldaoud, Dr. Aldaoud / Dr. Schwarzer, Leipzig Prof. Dr. med. Michael Koenigsmann, Ges. für Medizinstatistik + Projektentwicklung,, Hannover Prof. Dr. med. Thomas Frieling, Medizinische Klinik II, Helios Klinikum Krefeld, Krefeld Dr. med. Rudolf Schlag, Praxis Innere Medizin, Würzburg Dr. med. Godehard Obst, Praxis für Innere Medizin, Burgwedel Dr. med. Jan Knoblich, Onco Studies Lörrach, An der Onkologie Dreiländereck, Lörrach Dr. med. Rudolf Peceny, Hämatologie, Onkologie und Blutstammzelltransplantation, Klinikum Osnabrück GmbH, Osnabrück Ellen Ritter, Hämatologie u. Internistische Onkologie, Universitätsklinikum Jena, Jena Dr. med. Iris Zirpel, Praxisgemeinschaft, Oldenburg Prof. Dr. med. Heinz-Gert Höffkes, Tumorklinik, MVZ Osthessen, Klinikum Fulda, Fulda Dr. med. Florian Fauth, Gemeinschaftspraxis, Hanau Prof. Dr. med. Michael Heike, Medizinische Klinik / Onkologie, Kliniken Dortmund ggmbh, Dortmund Dr. med. Alexander Scherpe, MVZ, Stade Dr. med. Eva Römer, Innere Medizin I, Klinikum Idar-Oberstein GmbH, Idar-Oberstein Dr. med. Christian Andreas Schmidt, Innere Medizin C Abt. Hämatologie / Onkologie, Ernst-Moritz-Arndt-Universität, Greifswald Dr. med. Stefan Fuxius, Onkologische Schwerpunktpraxis Heidelberg, Heidelberg Dr. med. Sigrun Müller-Hagen, Dres. Müller-Hagen/Bertram, Forschungsgesell. für Malignität und Resultate GbR, Hamburg Dr. med. Ines Schade, Innere Medizin, Ruppiner Kliniken GmbH, Neuruppin Priv. Doz. Dr. med. Mathias Hänel, Klinik für Innere Medizin III / Studiensekretariat, Klinikum Chemnitz, Chemnitz Dr. med. Manfred Glados, Onkologische Schwerpunktpraxis, Coesfeld Dr. med. Burkhard Schmidt, Onkologische Schwerpunktpraxis,, München Dr. med. Christina Limmroth, Innere Abteilung, Krankenhaus Köln Holweide, Köln Dr. med. Ute Kreibich, Klinik für Innere Medizin III, Heinrich-Braun-Klinikum Zwickau ggmbh, Zwickau Dr. med. Christoph Diekmann, Med. Klinik Abt. Hämatologie / Onkologie, Evang. Diakoniekrankenhaus, Bremen Priv. Doz. Dr. med. Michael Sandherr, Gemeinschaftspraxis, Weilheim Priv. Doz. Dr. med. Ingo Tamm, Onkologische Schwerpunkpraxis Kurfürstendamm,, Berlin 5

HD8: Outcome of interim PET- positive advanced stage Hodgkin lymphoma Dr. med. Ludwig Fischer von Weikersthal, Onkologie/Hämatologie, Gesundheitszentrum St. Marien GmbH, Amberg Dr. med. Michael Niedermeier, Internistisches Facharztzentrum,, Memmingen Prof. Dr. med. Martin Bentz, Medizinische Klinik III, Städtisches Klinikum Karlsruhe, Karlsruhe Priv. Doz. Dr. med. Rainer Ordemann, Medizinische Klinik I, Universitätsklinik C.G. Carus, Dresden Dr. med. Lothar Müller, Schwerpunktpraxis, Leer Prof. Dr. med. Hans-Josef Weh, Med. Klinik II Abt. Hämatologie/Onkologie, St. Franziskus Hospital, Bielefeld Dr. med. Alexander Regnery, Onkologisches Zentrum, AMEOS Klinikum, Bremerhaven Dr. med. Andreas Jakob, Medizinische Klinik II, Hämatologie, Onkologie, Ortenau Klinikum Offenburg Gengenbach, Offenburg Priv. Doz. Dr. med. Christian Scholz, Klinik für Innere Medizin, Vivantes Klinikum am Urban, Berlin Dr. med. Frank Heits, I. Med. Klinik, Diakoniekrankenhaus, Rotenburg/ Wümme Dr. med. Thomas Kubin, Med.Abteilung 5/ Hämatologie, Klinikum Traunstein, Traunstein Dr. med. Birgit Schmid, Innere Medizin III, Marienhospital, Stuttgart Dipl.-Med. Steffen Dörfel, Onkologische Gemeinschaftspraxis, Dresden Dr. med. Erik Engel, Gemeinschaftspraxis, HOPA, Hamburg Dr. med. Dennis Hahn, Klinik für Onkologie, Klinikum Stuttgart, Stuttgart Dr. med. Thomas Zehrfeld, Innere Medizin Hämatologie/Onkologie, Kreiskrankenhaus Torgau, Torgau Prof. Dr. med. Maike de Wit, MVZ Hämatologie und Onkologie, Vivantes Netzwerk für Gesundheit, Berlin Dr. med. Lothar Schulz, Innere Medizin, Klinikum Garmisch-Partenkirchen, Garmisch-Partenkirchen Prof. Dr. med. Hans Tesch, Onkologische Gemeinschaftspraxis, Frankfurt Dr. med. Jürgen Wehmeyer, Praxis, Münster Prof. Dr. med. Burkhard Hennemann, Med. Klinik II, Hämatologie / Onkologie, Johanniter-Krankenhaus Rheinhausen GmbH, Duisburg Dr. med. Johannes Atta, Innere Medizin, Abt. für Hämatologie, z.hd. Frau Sabine Hug, Universitätsklinikum Frankfurt am Main, Frankfurt Dr. med. Christiane Hinske, Onkologische Gemeinschaftspraxis Würselen,, Würselen Dr. med. Martine Klausmann, Gemeinschaftspraxis, Aschaffenburg Dr. med. Gabriele Doering, Onkologische Praxis, Bremen Dr. med. Torsten Kamp, Hämat.-Onkologische Gemeinschaftspraxis, Wendlingen Priv. Doz. Dr. med. Alexander Schmittel, Hämatologie, Onkologie u. Tumorimmunologie, Charite Campus Benjamin Franklin, Berlin Prof. Dr. med. Frank Kullmann, Medizinische Klinik I, Klinikum Weiden, Weiden Prof. Dr. med. Christoph Salat, Hämatologische Schwerpunktpraxis, München Priv. Doz. Dr. med. Kathleen Jentsch-Ullrich, Gemeinschaftspraxis, Magdeburg Priv. Doz. Dr. med. Gernot Seipelt, Praxis für Internistische Onkologie, Bad Soden/Ts. Priv. Doz. Dr. med. Otto Prümmer, Innere Medizin III - Hämatologie und Onkologie, Klinikum Kempten / Oberallgäu ggmbh, Kempten / Allgäu Prof. Dr. med. Holger Hebart, Zentrum für Innere Medizin, Staufer Klinikum, Mutlangen Prof. Dr. med. Dirk Strumberg, Abteilung Hämatologie / Onkologie, Marienhospital Herne, Herne 6